Mitizax: Phase III data

Top-line data from the double-blind, European Phase III MITRA (MT-04) trial in 834 patients with house dust mite-induced allergic asthma showed that once-daily HDM AIT for up to 18 months met the primary endpoint of reducing

Read the full 363 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE